Novel Cancer Drug(s)
Cancer
Pre-clinicalActive
Key Facts
About BioFactura
BioFactura is a private, clinical-stage biotech company with a diversified portfolio spanning biosimilars, biodefense, and novel therapeutics. Its core asset is the patented StableFast™ Biomanufacturing Platform, designed to produce biologics faster, with higher yields, and at lower cost. The company generates revenue through government contracts and grants, particularly for biodefense programs, and has recently launched a CDMO division, Capitol Biologics, to expand its service offerings. With a pipeline featuring both internal and partnered programs in various stages of development, BioFactura operates at the intersection of commercial healthcare and government-funded biodefense.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |